18
3
7
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T12189 |
NBDHEX
|
Apoptosis; Glutathione Peroxidase; Autophagy | Apoptosis; Autophagy; Metabolism |
NBDHEX 是一种谷胱甘肽 S-转移酶 P1-1 抑制剂,也是晚期自噬抑制剂。它诱导肿瘤细胞凋亡,通过抑制 GST 的催化活性,避免抑制剂被特异性泵从细胞中排出,以及破坏 GSTP1-1和关键信号传导因子之间的相互作用,从而起到抗癌的作用。 | |||
T9688 |
CC-90001
|
JNK | MAPK |
CC-90001 是口服有效的 c-Jun N 末端激酶选择性抑制剂。在基于细胞的模型中,CC-90001显示出对JNK1的选择性是JNK2的 12.9 倍。CC-90001在特发性肺纤维化方面有研究价值。 | |||
T9010 |
IMM-H007
|
Others; AMPK | Chromatin/Epigenetic; Others; PI3K/Akt/mTOR signaling |
IMM-H007 是一种新型降脂剂,可增加 abca1 蛋白的表达。 | |||
T5097 |
Ezatiostat
TER199(free base),TLK199 |
Apoptosis; Glutathione Peroxidase; GST | Apoptosis; Metabolism; oxidation-reduction |
Ezatiostat (TER199(free base)) 是一种谷胱甘肽的三肽类似物,也是一种选择性的口服活性的谷胱甘肽 S-转移酶 P1-1 (GSTP1) 抑制剂。它通过抑制GSTP1导致 JNK 激活,刺激淋巴细胞生成和骨髓祖细胞增殖,可研究骨髓增生异常综合症。 | |||
T22776 |
Ezatiostat hydrochloride
TLK199 HCl,Ezatiostat盐酸盐,TER199 |
Glutathione Peroxidase | Metabolism |
Ezatiostat hydrochloride (TLK199 HCl) 是一种新型谷胱甘肽类似物,可刺激淋巴细胞生成和骨髓祖细胞增殖,可用于治疗血细胞减少症和研究骨髓增生异常综合症。它也是口服活性的选择性谷胱甘肽 S-转移酶 P1-1 抑制剂,通过抑制 GSTP1导致 JNK 激活。 | |||
T7677 |
JNK Inhibitor VIII
TCS JNK 6o |
JNK | MAPK |
JNK Inhibitor VIII (TCS JNK 6o) 是一种 c-Jun N-末端激酶(JNK-1, -2, -3)抑制剂,对 JNK-1、JNK-2 的IC50值分别是 45 nM 和 160 nM,对JNK-1、JNK-2、JNK-3 的Ki 分别为 2 nM、4 nM、52 nM。 | |||
T2343 |
AS601245
|
JNK | MAPK |
AS601245 是 c-Jun NH2-末端激酶 (JNK) 的抑制剂,具有神经保护特性。 | |||
T3598 |
JNK-IN-7
JNK inhibitor |
JNK | MAPK |
JNK-IN-7 (JNK inhibitor) 是 JNK 抑制剂,抑制 JNK1、JNK2和 JNK3,IC50分别为 1.5、2 和 0.7 nM。 | |||
TP1897L1 |
JIP-1 (153-163) acetate(438567-88-5 free base)
|
JNK | MAPK |
JIP-1 (153-163) acetate(438567-88-5 free base) 是c-Jun N-末端激酶 (JNK) 的肽抑制剂,基于 JNK-interacting protein-1 (JIP-1) 的残基 153-163。以微摩尔范围内的亲和力与 JNK 结合,并抑制 p38 和 ERK。 | |||
T5833 |
CC-401 Hydrochloride
CC401 HCl |
JNK | MAPK |
CC-401 Hydrochloride (CC401 HCl) 是 JNK 抑制剂(Ki= 25~50 nM)。 | |||
T3627 |
IQ-1S free acid
IQ-1,IQ-1S,IQ-1S (free acid) |
NF-κB; JNK | MAPK; NF-κB |
IQ-1S free acid (IQ-1S) 是 NF-κB/激活蛋白1 (AP-1) 抑制剂(IC50:2.3±0.41 μM)。它对 JNK1(Kd:240 nM)、JNK2(Kd:360 nM) 和 JNK3(Kd:100 nM)的都具有高的结合亲和力 。 | |||
T13779 |
MPT0B392
|
Others | Others |
MPT0B392 is an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation. | |||
T69527 |
Erioflorin
|
Others | Others |
Erioflorin is an ATP-competitive selective c-Jun N-terminal kinase (JNK) inhibitor. | |||
TP2134 |
c-JUN peptide
|
||
Peptide comprising residues 33 - 57 of the JNK binding (δ) domain of human c-Jun. Disrupts JNK/c-Jun interaction leading to inhibition of serum-induced c-Jun phosphorylation, up-regulation of p21cip/waf and modulation of inflammatory gene expression. Spec | |||
TP1897 |
JIP-1(153-163)
JIP-1 (153-163) |
||
JIP-1(153-163) is a peptide inhibitor of c-Jun N-terminal kinase (JNK), based on residues 153-163 of JNK-interacting protein-1 (JIP-1). JIP-1(153-163) binds to JNK with affinity in the micromolar range and minimally inhibits p38 and ERK. | |||
T16721 |
Ralimetinib
LY2228820 |
Others | Others |
Ralimetinib selectively inhibits phosphorylation of MK2 (Thr334) and has no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. Ralimetinib is an effective and selective, ATP-competitive inhibitor of p38 MAPK α/β (IC50s: 5.3 and 3. | |||
T36673 |
CC 401 dihydrochloride
|
Others | Others |
High affinity JNK inhibitor (Ki values are 25-50 nM). Inhibits JNK via competitive binding of the ATP-binding site of active, phosphorylated JNK. Exhibits > 40-fold selectivity for JNK over p38, ERK, IKK2, protein kinase C, Lck and ZAP70. Hepatoprotective. Also inhibits HCMV replication. Uehara et al (2004) c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation. 78 324 PMID:15316358 |Uehara et al (2005) JNK mediates hepatic ischemia reperfusion injury. J... | |||
T79489 |
JNK-1-IN-2
|
JNK | MAPK |
JNK-1-IN-2(Compound c6)是一种选择性JNK-1抑制剂,其IC50值为33.5 nM。同时,该化合物对JNK-2和JNK-3也具有抑制作用,其IC50值分别为112.9 nM和33.2 nM。通过抑制c-Jun蛋白的磷酸化,JNK-1-IN-2能够逆转肺部损伤,并且可以被应用于肺纤维化的相关研究。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3755 |
Pinostilbene
|
Others | Others |
Pinostilbene 是一种 Pterostilbene 的主要代谢物,能够抑制结肠癌细胞。 | |||
T3908 |
10-Gingerol
10-姜酚 |
Apoptosis | Apoptosis |
10-Gingerol 是一种姜根脂的主要刺激性成分,具有抗炎、抗氧化和抗增殖作用,能够抑制 MDA-MB-231 肿瘤细胞的增殖(IC50:12.1 μM)。 | |||
T6S1597 |
Mulberroside A
桑皮苷 A,桑皮苷A |
TNF; Tyrosinase; Interleukin | Apoptosis; Immunology/Inflammation; Proteases/Proteasome |
Mulberroside A 是桑中的一种主要活性成分,可降低TNF-α、IL-1β和IL-6的表达,抑制 NALP3、caspase-1 和 NF-κB 的激活以及 ERK、JNK 和 p38 的磷酸化 。它抑制蘑菇酪氨酸酶,具有抗炎和抗细胞凋亡作用。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04572 |
MKK4 Protein, Mouse, Recombinant (His & GST)
MKK4,MEK4,PRKMK4,Sek1,JNKK1,Serk1,mitogen-ac |
Mouse | Baculovirus Insect Cells |
Dual specificity mitogen-activated protein kinase kinase 4, also known as MAP kinase kinase 4, MAPKK4, JNK-activating kinase 1, MAPK/ERK kinase 4, SAPK/ERK kinase 1, c-Jun N-terminal kinase kinase 1, JNKK, and MAP2K4, is a protein that belongs to the protein kinase superfamily, STE Ser/Thr protein kinase family and MAP kinase kinase subfamily. MAP2K4 / JNKK1 is a protein kinase that is a direct activator of MAP kinases in response to various environmental stresses or mitogenic stimuli. MAP2K4 / ... | |||
TMPH-01251 |
DUSP26 Protein, Human, Recombinant (His & SUMO)
MKP-8,NATA1,DSP-4,SKRP3,DUSP26,MKP8,LDP-4,LDP4,DUSP24,Dual s... |
Human | E. coli |
Inactivates MAPK1 and MAPK3 which leads to dephosphorylation of heat shock factor protein 4 and a reduction in its DNA-binding activity. Inhibits MAP kinase p38 by dephosphorylating it and inhibits p38-mediated apoptosis in anaplastic thyroid cancer cells. Can also induce activation of MAP kinase p38 and c-Jun N-terminal kinase (JNK). | |||
TMPY-02444 |
ATF2 Protein, Human, Recombinant (His & GST)
CREB2,CRE-BP1,CREB-2,TREB7,ac... |
Human | Baculovirus Insect Cells |
Activating transcription factor 2, also known as ATF2, is a member of the leucine zipper family of DNA-binding proteins that binds to the cAMP response element. Its activity is enhanced after phosphorylation by stress-activated protein kinases such as c-Jun N-terminal kinase and p38. ATF2 has been found to be a target of the JNK signal transduction pathway and mediate adenovirus E1A-inducible transcriptional activation. ATF2 is also been reported playing roles in TGF-β signaling pathway. It has ... | |||
TMPY-04425 |
PRAK/MAPKAPK5 Protein, Human, Recombinant (His & GST)
PRAK,MAPKAP-K5,MK-5,mitogen-activated protein kinas... |
Human | Baculovirus Insect Cells |
MAPKAPK5 contains 1 protein kinase domain and belongs to the protein kinase superfamily, CAMK Ser/Thr protein kinase family. MAPKAPK5 has significant sequence homology to mitogen-activated protein kinase (MAPK)-activated protein kinase (MAPKAPK). It is widely distributed. MAPKAPK5 can be phosphorylated by an extracellular-regulated kinase (ERK), and p38 kinase but not by c-jun N-terminal kinase (JNK)in vitro. Recombinant GST-MAPKAPK5 protein can phosphorylate a peptide derived from the regulator... | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |